Summary
(Midwestern and Northeast USA)
EMRClaims+ database is a proprietary database managed by eMAX Health. The database integrates EMR details with longitudinal claims for complete patient follow-up including lab results. The EMRClaims+ database is derived through contracted payer, provider, and specialty pharmacy networks in order to provide comprehensive data on healthcare service and all aspects of clinical care for >20 million patients treated across 9 states of the United States from Midwest to the Northeast since 1988. Data from Northeastern USA were added to the database in 2016, although the information contained in the Northeast component goes back to 2000. The Northeast component of the data includes de-identified, EMR based data extracts from care provided to more than 2 million residents throughout northeast US representing both inpatient and outpatient settings, as well as medical, hospital and pharmacy claims.
The database accesses administrative insurance claims and links that to an overlapping provider database of electronic medical records (EMR). An approximate 3.1 million facility encounters are added each year. The database also tracks 675,000 commercially insured lives linked with EMR through provider-aligned patient panels, managed care membership files, and a Master Patient Index via a medical record number (i.e., lifetime patient identifier). All EMR, including medication orders and administrative database elements, are available for periods as recent as 30 days from the time of extract.
EMR & Claims Data includes:
- patient demographics
- physician appointments
- clinic visit notes
- clinical laboratory results
- radiology results
- cardiology results
- neurological procedure reports
- anatomic pathology and cytopathology
- operative reports
- operating room procedures
- discharge summaries
- ambulatory care visits (outpatient and emergency department)
- hospital admissions
- inpatient pharmacy
- inpatient medications
- vital signs
- medication orders
- pharmacy and medical claims
Specialty data include, but not limited to, are found in the areas of:
- Oncology (stage, tumor size, follow-up, etc.)
- Pulmonology (PFT results, etc.)
- Rheumatology (BMD, T-Scores, etc.)
- Cardiology (Ejection Fraction, PCI, etc.)
- Geriatrics (MMSE, etc.), and more.
Diagnosis, procedure, and drug data are captured from various sources: The administrative billing data include ambulatory care visits, hospital admissions, operating room procedures, and ancillary services. The full EMR data include clinical laboratory, inpatient pharmacy, and vital signs data. The longitudinal insurance claims data include pharmacy benefit and medical benefit information. Additionally, electronic provider and patient surveys may be customized upon request in order to assess attitudes and preferences.
(EMRClaims+ accesses administrative insurance claims and links them to an overlapping provider database of EMR)
All EMR, including medication orders and administrative database elements, are available for periods as recent as 30 days from the time of extract; census and death certificates are updated annually.
Data from Northeastern USA were added to the database in 2016, although the information contained in the Northeast component goes back to 2000.
NOTE: New data are always added depending on the year of the datacut.
EMRClaims+ is updated on a monthly basis.
This profile was last updated for the B.R.I.D.G.E. TO DATA site on June 27, 2025.
Population Dynamics
There are currently more than 20 million electronic records available across 9 states from the Midwest to the Northeast.
(There are approximately 5.5 million patients active in the database)
(~3.1 Million facility encounters are added each year)
(Not applicable as this database continues to collect data)
Demographic Data
Age (years)
< 18 years = 10%
> 65 years = 39%
Males = 48%
Females = 52%
9 states across Midwest and Northeast USA
This is recorded as mm/dd/yyyy but those data are not released.
Death certificates are received from the state of Michigan Vital Statistics department and matched with patient population to get date of death.
Data on marital status are captured
Physician & Practioner Info
Diagnoses/Signs & Symptoms
Diagnosis data in the administrative and EMR databases are obtained from:
- Clinic visit notes
- Discharge summaries
- Ambulatory care visits
- Hospital admissions
- Medical benefit claims
Additionally, patient-reported outcomes, as well as patient and prescriber preferences and attitudes may be obtained via customized electronic surveys upon request.
NOTE: Data from Northeastern USA were added to the database in 2016, although the information contained in the Northeast component goes back to 2000. Data are updated monthly and recency depends on the time period desired.
[Outpatient diagnoses include 1 primary diagnosis and up to 2 additional diagnoses (maximum 3). Up to 35 inpatient diagnoses may be recorded.]
Vital signs are captured.
NOTE: Pregnancy could be captured based on a diagnosis code or a CPT pregnancy encounter code.
Birth defect data are captured via ICD-9-CM and ICD-10-CM coding
Cancer data (diagnosis date and incident cases) are captured via ICD-9-CM coding as well as ICD-O-3 for site and histology (cell-type)
Infections can be coded with diagnosis codes, but specific organism can be captured in culture results
Behavioral data on smoking and alcohol use are routinely recorded but require manual review of patient charts and records
Procedures
Procedure data include:
- Clinical laboratory results
- Radiology results
- Cardiology results
- Operating room procedures
- Neurological procedure reports
- Ancillary services
- Anatomic pathology
- Cytopathology
NOTE: Data from Northeastern USA were added to the database in 2016, although the information contained in the Northeast component goes back to 2000. Data are updated monthly and recency depends on the time period desired.
Laboratory data include results from:
- Clinical lab tests
- Radiology
- Cardiology
- Neurological procedures
- Anatomic pathology
- Cytopathology.
Note: Some might require manual chart review to determine results.
Drug Information
(Drug data are obtained via pharmacy benefit claims and inpatient pharmacy EMRs; med orders can also be obtained.)
NOTE: Data from Northeastern USA were added to the database in 2016, although the information contained in the Northeast component goes back to 2000. Data are updated monthly and recency depends on the time period desired.
As of the addition of EPIC in 2013
However, the maximum number of drug codes allowed varies
(Not applicable)
Additional drug information includes:
- Dose information
- Date of prescription claim
- Prescription claim amount
- Refill or not
- Quantity of drug dispensed
- Brand name
- Generic name
Biobanks
Genetic-PGx Data
Economic Data
Cost data are only available for Midwestern, not for Northeastern US:
- Cost data on medical and pharmacy benefits are obtained via longitudinal insurance claims while cost data on ambulatory care visits
- Hospital admissions
- Operating room procedures
- Ancillary services are obtained via administrative billing data.
NOTE: For Midwestern USA only
Information is available on billing and insurance claims for Midwestern USA only, not for Northeastern USA
(Not applicable)
Validation & Linkage
However, a quality check is conducted at the time of data collection
Access to the full EMRs cannot be provided; however, requests for specific information from the EMRs can be granted with IRB approval from HFHS and when a data use agreement has been executed
The EMR data in EMRClaims+ is directly linked to commercial insurance databases such as MarketScan database
EMRClaims+ also tracks 675,000 commercially insured lives linked with EMR through provider-aligned patient panels, managed care membership files, and a Master Patient Index using a unique medical record number (i.e., patient identifier).
Administrative Information
Julian Casciano
CEO
eMAX Health
1686 S Federal Hwy
Suite 273
Delray Beach, FL 33483
USA
Phone: +1 (914) 304-8128
Fax: +1 (914) 206-4959
Email 1: juliancasciano@emaxhealth.net
Email 2: info@emaxhealth.net
1. Zenobia Dotiwala
eMAX Health
1686 S Federal Hwy
Suite 273
Delray Beach, FL 33483
USA
Email: zenobiadotiwala@emaxhealth.net
2. You may also complete the contact form on this page: https://emaxhealth.net/contact-emax-health/
(eMax Health)
(Not applicable)
N/A
(Not applicable)
(This is a proprietary database that is available to researchers for purchase)
Costs are dependent on the request
Access database
1. Hanania NA, Settipane RA, Khoury S, Shaikh A, Dotiwala Z, Casciano J, Foggs MB. Adding tiotropium or long-acting β2-agonists to inhaled corticosteroids: Asthma-related exacerbation risk and healthcare resource utilization. Allergy Asthma Proc. 2023 Nov 13;44(6):413-421.
2. Bender B, Oppenheimer J, George M, Brown R, Patel A, Hill T, Boe A, Mayen Herrera E, Dotiwala Z, Casciano J, Bernstein JA. Assessment of Real-World Escalation to Biologics in US Patients With Asthma. J Allergy Clin Immunol Pract. 2022 Nov;10(11):2941-2948.
3. Mauskop A, Lamerato L, Casciano J, Cohen JM, Thompson SF, Krasenbaum LJ, Dotiwala Z, Tangirala K, McAllister P. Improvements in Patient-reported Migraine Pain Intensity and Composite Migraine Symptoms With Fremanezumab in the Real World. Neurology. 2021 Apr; 96 (15 Supplement): 2114;
4. McAllister P, Casciano J, Cohen J, Thompson S, Krasenbaum L, Dotiwala Z, Tangirala K, Lamerato L. PND98 Real World IMPACT of Fremanezumab Treatment on Headache Frequency and Healthcare Resource Use Among US Patients with Episodic or Chronic Migraine. Value in Health. 2020 Dec 1;23:S640.
5. Diaz-Insa S, Santos S, Benhaddi H, Lee L, Thompson S, Goadsby PJ. PND99 The Humanistic Disease Burden of Episodic and Chronic Migraine in France, Spain and the United Kingdom. Value in Health. 2020 Dec 1;23:S640-1.
6. Dotiwala Z, Casciano J, Davis JR, Fox K, Gopalan G, Rastogi S, Lamerato L, Mathur SK. Effect of clinically significant thresholds of eosinophil elevation on health care resource use in asthma. Annals of Allergy, Asthma & Immunology. 2020 Aug 1;125(2):182-9.
7. Chipps B, Mosnaim G, Mathur SK, Shaikh A, Khoury S, Gopalan G, Palli SR, Lamerato L, Casciano J, Dotiwala Z, Settipane R. Add-on tiotropium versus step-up inhaled corticosteroid plus long-acting beta-2-agonist in real-world patients with asthma. Allergy Asthma Proc. 2020 Jul 1;41(4):248-255.
8. Bellanti JA, Settipane RA. COVID-19, allergic disease and asthma: Extraordinary challenges for the allergist/immunologist. Allergy Asthma Proc. 2020 Jul 1;41(4):229-231.
9. Casciano J, Krishnan J, Buatti-Small M, Li C, Dotiwala Z. Martin B. Progression to Uncontrolled Severe Asthma: A novel risk equation. J Manag Care Spec Pharm, 2017 Jan; 23(1):44-50.
10. Casciano J, Krishnan J, Dotiwala Z, Li C, Sun S. Clinical and Economic Burden of Elevated Blood Eosinophilia in Patients with and without Uncontrolled asthma. J Manag Care Spec Pharm, 2017 Jan; 23(1):85-91.
Database Contact
Julian Casciano
CEO
eMAX Health
1686 S Federal Hwy
Suite 273
Delray Beach, FL 33483
USA
Phone: +1 (914) 304-8128
Fax: +1 (914) 206-4959
Email 1: juliancasciano@emaxhealth.net
Email 2: info@emaxhealth.net
1. Zenobia Dotiwala
eMAX Health
1686 S Federal Hwy
Suite 273
Delray Beach, FL 33483
USA
Email: zenobiadotiwala@emaxhealth.net
2. You may also complete the contact form on this page: https://emaxhealth.net/contact-emax-health/
Literature References
1. Hanania NA, Settipane RA, Khoury S, Shaikh A, Dotiwala Z, Casciano J, Foggs MB. Adding tiotropium or long-acting β2-agonists to inhaled corticosteroids: Asthma-related exacerbation risk and healthcare resource utilization. Allergy Asthma Proc. 2023 Nov 13;44(6):413-421.
2. Bender B, Oppenheimer J, George M, Brown R, Patel A, Hill T, Boe A, Mayen Herrera E, Dotiwala Z, Casciano J, Bernstein JA. Assessment of Real-World Escalation to Biologics in US Patients With Asthma. J Allergy Clin Immunol Pract. 2022 Nov;10(11):2941-2948.
3. Mauskop A, Lamerato L, Casciano J, Cohen JM, Thompson SF, Krasenbaum LJ, Dotiwala Z, Tangirala K, McAllister P. Improvements in Patient-reported Migraine Pain Intensity and Composite Migraine Symptoms With Fremanezumab in the Real World. Neurology. 2021 Apr; 96 (15 Supplement): 2114;
4. McAllister P, Casciano J, Cohen J, Thompson S, Krasenbaum L, Dotiwala Z, Tangirala K, Lamerato L. PND98 Real World IMPACT of Fremanezumab Treatment on Headache Frequency and Healthcare Resource Use Among US Patients with Episodic or Chronic Migraine. Value in Health. 2020 Dec 1;23:S640.
5. Diaz-Insa S, Santos S, Benhaddi H, Lee L, Thompson S, Goadsby PJ. PND99 The Humanistic Disease Burden of Episodic and Chronic Migraine in France, Spain and the United Kingdom. Value in Health. 2020 Dec 1;23:S640-1.
6. Dotiwala Z, Casciano J, Davis JR, Fox K, Gopalan G, Rastogi S, Lamerato L, Mathur SK. Effect of clinically significant thresholds of eosinophil elevation on health care resource use in asthma. Annals of Allergy, Asthma & Immunology. 2020 Aug 1;125(2):182-9.
7. Chipps B, Mosnaim G, Mathur SK, Shaikh A, Khoury S, Gopalan G, Palli SR, Lamerato L, Casciano J, Dotiwala Z, Settipane R. Add-on tiotropium versus step-up inhaled corticosteroid plus long-acting beta-2-agonist in real-world patients with asthma. Allergy Asthma Proc. 2020 Jul 1;41(4):248-255.
8. Bellanti JA, Settipane RA. COVID-19, allergic disease and asthma: Extraordinary challenges for the allergist/immunologist. Allergy Asthma Proc. 2020 Jul 1;41(4):229-231.
9. Casciano J, Krishnan J, Buatti-Small M, Li C, Dotiwala Z. Martin B. Progression to Uncontrolled Severe Asthma: A novel risk equation. J Manag Care Spec Pharm, 2017 Jan; 23(1):44-50.
10. Casciano J, Krishnan J, Dotiwala Z, Li C, Sun S. Clinical and Economic Burden of Elevated Blood Eosinophilia in Patients with and without Uncontrolled asthma. J Manag Care Spec Pharm, 2017 Jan; 23(1):85-91.